Model-informed AUC-guided dosing for parenteral vancomycin in critically ill patients: impact on target attainment and renal safety - a pre-post intervention study.

Laura Gundlach, Mareike Kunkel, Oliver Scherf-Clavel, Güzin Surat

Abstract read

In one paragraph

Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Laura GundlachPharmacy, University Hospital Wuerzburg, 97076, Wuerzburg, Germany. gundlach_l@ukw.de.

Mareike KunkelPharmacy, University Hospital Wuerzburg, 97076, Wuerzburg, Germany.

Oliver Scherf-ClavelDepartment of Pharmacy, Ludwig-Maximilians-University, Clinical Pharmacy and Pharmacotherapy, 81377, Munich, Germany.

Güzin SuratUnit for Infection Control and Antimicrobial Stewardship, University Hospital Wuerzburg, 97080, Wuerzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParenteral vancomycin is essential for the treatment of certain gram-positive infections but is associated with acute kidney injury (AKI). The 2020 IDSA guideline recommends AUC

methodsThis pre-post intervention study compared a retrospective group (January 1, 2019 - June 30, 2021) with a prospective group (October 17, 2022 - December 31, 2023), including critically ill patients from intensive and intermediate care units. The prospective group received AUC

resultsAKI occurred in 27.8% of the retrospective group and 14.0% of the prospective group (p = 0.04). The AUC-based group achieved therapeutic targets more frequently (70.2% vs. 55.1%, p = 0.049) and had fewer supratherapeutic levels (8.8% vs. 24.5%, p = 0.01).

conclusionsAUC

Indexed as

Acute Kidney InjuryAnti-Bacterial AgentsVancomycinAgedArea Under CurveBayes TheoremCritical IllnessFemaleHumansMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedProspective StudiesRetrospective StudiesStaphylococcal InfectionsAnti-Bacterial AgentsVancomycinAKIAntimicrobial stewardshipAUC24-based dosingMIPDMRSANon-MRSATarget attainmentVancomycin

Identifiers

PMID42760572

DOI10.1186/s40360-026-01224-x

PMCPMC13589384

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.